SHCBP1L: A Potential Drug Target and Biomarker (G81626)

Target Name: SHCBP1L

NCBI ID: G81626

SHCBP1L

SHCBP1L: A Potential Drug Target and Biomarker

ShcBP1L, also known as SHCBP1-like protein, is a protein that belongs to the family of SHCBP proteins, which are known for their role in intracellular signaling. SHCBP proteins have been identified as potential drug targets in various diseases, including cancer, neurodegenerative diseases , and developmental disorders. In this article, we will discuss the potential drug targeting potential of SHCBP1L and its potential as a biomarker for various diseases.

Potential Drug Target

SHCBP1L is a 21-kDa protein that is expressed in various tissues and cells, including liver, muscle, heart, and brain. It is highly conserved and has a similar structure to other SHCBP proteins, including SHCBP2, SHCBP3, and SHCBP4. SHCBP1L is known to localize to the endoplasmic reticulum (ER) and to play a role in intracellular signaling.

Studies have shown that SHCBP1L can interact with various intracellular signaling pathways, including the TGF-β pathway, the PI3K/Akt pathway, and the NF-kappa-B pathway. It is also known to be involved in the regulation of cell adhesion, migration, and invasion.

Given its involvement in intracellular signaling, SHCBP1L is a potential drug target for various diseases. SHCBP1L has been shown to be overexpressed in various diseases, including cancer, neurodegenerative diseases, and developmental disorders. Therefore, inhibiting SHCBP1L activity could be a promising strategy for treating these diseases.

Potential Biomarkers

SHCBP1L has also been identified as a potential biomarker for various diseases. Its expression has been shown to be associated with the development and progression of various diseases, including cancer, neurodegenerative diseases, and developmental disorders.

For example, studies have shown that SHCBP1L is overexpressed in various types of cancer, including breast, ovarian, and colorectal cancer. Therefore, SHCBP1L has been identified as a potential biomarker for cancer.

In addition to cancer, SHCBP1L has also been shown to be involved in the development and progression of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. Therefore, SHCBP1L could also be used as a biomarker for neurodegenerative diseases.

SHCBP1L has also been shown to be involved in the development and progression of developmental disorders, such as Down syndrome and Fragile X syndrome. Therefore, SHCBP1L could also be used as a biomarker for developmental disorders.

Conclusion

In conclusion, SHCBP1L is a protein that has been identified as a potential drug target for various diseases. Its conserved structure and involvement in intracellular signaling pathways make it a promising candidate for drug development. Furthermore, its potential as a biomarker for various diseases makes it an attractive target for diagnostic studies.

Further research is needed to fully understand the role of SHCBP1L in disease progression and to identify small molecules that can specifically inhibit its activity. Once its full potential has been understood, SHCBP1L could be a valuable tool for the development of new treatments for various diseases.

Protein Name: SHC Binding And Spindle Associated 1 Like

Functions: Testis-specific spindle-associated factor that plays a role in spermatogenesis. In association with HSPA2, participates in the maintenance of spindle integrity during meiosis in male germ cells

The "SHCBP1L Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SHCBP1L comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets